Gut microbiota, angiotensin-converting enzyme, celiac disease, and risk of COVID-19 infection: a review

Fahimeh Sadat Gholam-Mostafaei; Tina Didari; Marzieh Ramandi; Reza Vafaee; Mohammad Rostami-Nejad

Gut microbiota, angiotensin-converting enzyme, celiac disease, and risk of COVID-19 infection: a review

Gastroenterol Hepatol Bed Bench. 2021 Fall;14(Suppl1):S24-S31.

Authors

Fahimeh Sadat Gholam-Mostafaei¹, Tina Didari^{2

3}, Marzieh Ramandi⁴, Reza Vafaee⁵, Mohammad Rostami-Nejad¹

Affiliations

¹ Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
² Pharmaceutical Products Technology Development Center, Tehran University of Medical Sciences, Tehran, Iran.
³ Co-first author.
⁴ Proteomics Research Center, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
⁵ Laser Application in Medical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

PMID: 35154599
PMCID: PMC8817746

Abstract

Celiac disease (CD) is an autoimmune disorder of the gastrointestinal tract in a genetically susceptible person. Gluten is the most crucial trigger factor for CD, and environmental factors such as microbiota and opportunistic infection risk its pathogenesis. Coronavirus disease 19 (COVID-19) spread rapidly and became a problem for healthcare systems worldwide. Little is known about the risk of severe COVID-19 and the role of dysbiosis among patients with CD. There is also a lack of knowledge about the effects of CD gut microbiota on COVID-19 infection. Therefore, the current review discusses the relationship between CD and risk factors such as microbiota for susceptibility to COVID-19.

Keywords: ACE2 receptor; COVID-19; Celiac disease; Gut microbiota; SARS-CoV-2.

Publication types

Review